Quest Diagnostics director adds shares via DRIP
Quest Diagnostics director Vicky B. Gregg increased her direct holdings through a dividend reinvestment plan.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Quest Diagnostics director Vicky B. Gregg increased her direct holdings through a dividend reinvestment plan. On April 20, 2026, she acquired 68 shares of Quest Diagnostics common stock at $194.698 per share via a broker-administered dividend reinvestment program. Following this automatic acquisition, she directly owns 17,172 shares of common stock. The filing notes this dividend reinvestment transaction was eligible for deferred reporting on Form 5, but she chose to report it early on Form 4.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 68 | $194.698 | $13K |
Footnotes (1)
- F1. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5. The reporting person has chosen to report such transaction early on this Form 4.
Key Figures
Key Terms
dividend reinvestment plan financial
Form 5 regulatory
Form 4 regulatory
Grant, award, or other acquisition financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Quest Diagnostics (DGX) report for Vicky B. Gregg?
Why was this Quest Diagnostics (DGX) dividend reinvestment transaction reported on Form 4?
What does the transaction code 'A' mean in this Quest Diagnostics (DGX) Form 4?
AI-generated analysis. How Rhea-AI works. Not financial advice.